HighGravityDataAshland — Feb 2, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001193125-26-033842
Showing in the filing
Temporary impacts from the Calvert City startup delay and recent weather-related disruptions
“approximately $11 million”
Period
Q2 FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 8
Temporary impacts from the Calvert City star… for Q2 FY2026
“approximately $11 million”
Sales for FY2026
“$1,835 million to $1,905 million”
Adjusted EBITDA for FY2026
“$400 million to $420 million”
Adjusted Diluted Earnings Per Share Excludin… for FY2026
“double digit plus growth”
Ongoing Free Cash Flow Conversion for FY2026
“approximately 50 percent of Adjusted EBITDA”
Capital expenditures for FY2026
“approximately $100 million”
Cost savings under the $90 million dollar pr… for FY2026
“approximately $30 million”
Manufacturing optimization program cost savi… for FY2026
“approximately $30 million in cost savings under the $90 million dollar program”
Exhibit 99.1 · the passage around this item
… earlier in the release
A declined three percent • Cash flows provided by operating activities of $125 million; Ongoing Free Cash Flow 2 of $26 million • Narrowing full‑year fiscal 2026 Adjusted EBITDA guidance to $400–$420 million, reflecting approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions, isolated to the second quarter WILMINGTON, Del., February 2, 2026 – Ashland Inc. (NYSE: ASH) today announced financial results 1 for the first quarter of fiscal year 2026, which ended December 31, 2025, and narrowed its full-year fiscal 2026 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings. “Ashland’s first‑quarter performance reflects our disciplined execution and ability to deliver resilient results despite mixed demand conditions,” said Guillermo Novo, chair and chief executive officer of Ashland. “While overall sales declined modestly, primarily within Specialty Additives, we delivered solid margins supported by cost actions, improved product mix, and continued benefits from our portfolio optimization initiatives. Life Sciences achieved year‑over‑year growth driven by healthy pharma demand and strong innovation momentum. Personal Care delivered resilient results, supported by strong performance in biofunctional actives a
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.